Recent Updates — SAVA

Filana Therapeutics reported Q2 2026 net loss of $8.6 million ($0.18 per share), a significant improvement from the $44.2 million loss in the prior year period driven by the absence of a $31.25 million securities litigation contingency recorded in 2025. The company paid $31.25 million into escrow on July 23, 2026, to settle this litigation. Cash and cash equivalents stood at $82.7 million as of June 30, 2026, with no debt. R&D expenses decreased 35% year-over-year to $3.3 million following the phase-out of its Alzheimer’s disease program. The company is actively engaging with the FDA to lift a clinical hold on its simufilam proof-of-concept trial for TSC-related epilepsy and expects unrestricted cash at year-end 2026 to range from $36 to $40 million. Filana Therapeutics, Inc. operates in the biotechnology industry, developing investigational therapies for central nervous system disorders such as tuberous sclerosis complex-related epilepsy.